Acute Myeloid Leukaemia

AML 17

The AML 17 trial has two distinct parts:

i.For patients with acute myeloid leukaemia (AML), (other than acute promyelocytic leukaemia) and High Risk Myelodysplasia, as defined by the WHO Classification (2001) (Appendix A, protocol).

ii.For adults with acute promyelocytic leukaemia (APL).

 

AC220 in patients with AML

A phase 2 open label, AC220 monotherapy efficacy study in patients with acute myeloid leukaemia (AML) with FLT3-ITD activating mutations.

RAVvA

 Phase II Randomised Trial of 5-Azacitidine versus 5-Azacitidine in combination with Vorinostat in patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes Ineligible for Intensive Chemotherapy.